Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor.
BACKGROUND
Anaphylactic reactions were a rare complication of low purity VIII concentrates, but not with high purity VIII concentrates.


METHODS
7 y/o WM with severe hemophilia A, received only cryoprecipitate and monoclonally purified VIII concentrates; developed post-infusional urticaria. A 2-Bethesda-unit inhibitor was detected. Generalized urticaria and bronchospasm following factor developed as the titer increased. Skin tests demonstrated reactivity to plasma derived VIII, but not recombinant VIII (rhVIII). Attempts at desensitization using rhVIII failed. ELISA revealed an anti-VIII IgE antibody. He was treated with a modified tolerance regimen using rhVIII starting at 500 U/day with aggressive premedication. The dosage increased by 200 U weekly as tolerated to a maximum of 100 U/kg/d without symptoms.


RESULTS
His antibody titer decreased rapidly once he started 100 U/kg/d. Six months later, the inhibitor was < 1 Bethesda unit.


CONCLUSIONS
Immune tolerance induction using a graduated dosage of rhVIII was successful.
Harper
J L
JL
Department of Pediatrics, University of Nebraska College of Medicine, Omaha, USA.
Gill
J C
JC
Hopp
R J
RJ
Evans
J
J
Haire
W D
WD
D000707:Anaphylaxis / Q000139:chemically induced*; D000906:Antibodies / Q000008:administration & dosage; D002648:Child; D005169:Factor VIII / Q000009:adverse effects* / Q000276:immunology; D006467:Hemophilia A / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D008297:Male
D000906:Antibodies; D005169:Factor VIII